Peijia Medical Ltd. (HK:9996) has released an update.
Peijia Medical Limited has announced a significant increase in revenue for the first half of 2024, with figures rising by approximately 28.9% to 37.8% compared to the previous year. This growth is largely due to the accelerated commercialization of their transcatheter aortic valve replacement products, increased sales of coil products via volume-based procurement, and market penetration of ischemic products with unique designs. Additionally, the newly approved DCwireTM Micro Guidewire has been well received in the market, further contributing to the company’s financial upturn.
For further insights into HK:9996 stock, check out TipRanks’ Stock Analysis page.
